drugset
drugset / Trial / NCT02171234

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

NCT02171234 ↗

Phase 1 Completed 32 enrolled Bial - Portela C S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of multiple dose regimens of BIA 2-093 in healthy young male volunteers

Timeline

Start
2001-02
Primary completion
2001-06
Completion
2001-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 200 mg Oral
Subject Eslicarbazepine acetate Unknown 400 mg Oral
Subject Eslicarbazepine acetate Unknown 800 mg Oral
Subject Eslicarbazepine acetate Unknown 1200 mg Oral

Indications

epilepsy